Lupin Signs Agreement with Huons for Mexico Launch

Lupin Limited (Lupin) announced a pivotal license and supply agreement with Huons Co. Ltd to register and market Cyclosporine Ophthalmic Nanoemulsion, 0.4mL Single-use Vial, in Mexico.

Advanced Technology for Treating Dry Eye Syndrome

Cyclosporine Ophthalmic Nanoemulsion, a preservative-free innovation, has garnered approvals in South Korea, Peru, and numerous Middle Eastern nations for its efficacy in treating dry eye syndrome and healing corneal ulcers. Utilizing advanced nanoparticle technology, this formulation accelerates relief by boosting tear production in patients with reduced tear formation linked to keratoconjunctivitis sicca-related ocular inflammatory disease.

"We are delighted to partner with Huons to introduce Cyclosporine Ophthalmic Nanoemulsion in Mexico and offer a novel technology that provides significant benefits to our patients suffering from Dry eye," stated Dr. Fabrice Egros, President – Corporate Development and Growth Markets, Lupin. "With this addition to our Ophthalmology portfolio, we continue to strengthen our commitment to provide better healthcare and Eyecare solutions to our patients, improving patient quality of life and vision."

Milestone for Huons and Strategic Expansion for Lupin

Mr. Yohun Aum, Senior Director – Head of Global Business Division, Huons, expressed enthusiasm about this collaboration: "Introducing our Cyclosporine Ophthalmic Nanoemulsion in Mexico is a significant milestone for Huons. We look forward to strengthening our partnership by supplying high-quality products for Mexico."

The agreement marks a strategic move for Lupin to expand its footprint in the Ophthalmology segment, leveraging Huons' expertise and robust product portfolio. The introduction of Cyclosporine Ophthalmic Nanoemulsion in Mexico underscores Lupin's commitment to addressing unmet medical needs and enhancing patient care across global markets.

For further updates and developments, Lupin and Huons are poised to advance their collaborative efforts in delivering innovative healthcare solutions, ensuring broader accessibility to advanced eye care treatments worldwide.